Whales with a great deal of cash to invest have actually taken a visibly bearish position on Praxis Accuracy Medication
Taking a look at choices history for Praxis Accuracy Medication (NASDAQ: PRAX) we spotted 8 trades.
If we think about the specifics of each trade, it is precise to state that 12% of the financiers opened trades with bullish expectations and 87% with bearish.
From the total spotted trades, 5 are puts, for an overall quantity of $635,535 and 3, calls, for an overall quantity of $139,650.
Forecasted Cost Variety
Taking into consideration the Volume and Open Interest on these agreements, it appears that whales have actually been targeting a cost variety from $120.0 to $200.0 for Praxis Accuracy Medication over the last 3 months.
Volume & & Open Interest Trends
Taking a look at the volume and open interest supplies essential insights into stock research study. This details is type in assessing liquidity and interest levels for Praxis Accuracy Medication’s choices at specific strike rates. Listed below, we provide a photo of the patterns in volume and open interest for calls and puts throughout Praxis Accuracy Medication’s considerable trades, within a strike cost variety of $120.0 to $200.0, over the previous month.
Praxis Accuracy Medication Call and Put Volume: 30-Day Summary
Largest Options Trades Observed:
| Sign | PUT/CALL | Trade Type | Belief | Exp. Date | Ask | Quote | Cost | Strike Cost | Overall Trade Cost | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRAX | PUT | SWEEP | BEARISH | 01/16/26 | $ 26.6 | $ 23.4 | $ 26.6 | $ 160.00 | $ 266.0 K | 0 | 100 |
| PRAX | PUT | SWEEP | BEARISH | 01/16/26 | $ 33.2 | $ 28.5 | $ 33.1 | $ 170.00 | $ 145.6 K | 7 | 44 |
| PRAX | PUT | SWEEP | BEARISH | 01/16/26 | $ 33.5 | $ 30.4 | $ 33.5 | $ 170.00 | $ 113.4 K | 7 | 103 |
| PRAX | PUT | TRADE | BEARISH | 01/16/26 | $ 33.5 | $ 30.2 | $ 33.1 | $ 170.00 | $ 66.2 K | 7 | 67 |
| PRAX | CALL | TRADE | BULLISH | 12/18/26 | $ 83.0 | $ 80.5 | $ 83.0 | $ 120.00 | $ 58.1 K | 113 | 7 |
About Praxis Accuracy Medication
Praxis Accuracy Medicines Inc is a clinical-stage biopharmaceutical business. The company is participated in equating hereditary insights into the advancement of treatments for clients impacted by main nerve system conditions identified by a neuronal excitation-inhibition imbalance. The business has actually created 3 clinical-stage item prospects, ulixacaltamide (previously called PRAX-944), vormatrigine (previously called PRAX-628), and relutrigine (previously called PRAX-562), along with PRAX-020 which has actually been in-licensed by UCB Biopharma SRL, or UCB.
Present Position of Praxis Accuracy Medication
- With a trading volume of 269,644, the cost of PRAX is down by -1.91%, reaching $165.0.
- Present RSI worths suggest that the stock is might be overbought.
- Next revenues report is arranged for 109 days from now.
What Experts Are Stating About Praxis Accuracy Medication
Over the previous month, 5 market experts have actually shared their insights on this stock, proposing a typical target cost of $269.8.
Turn $1000 into $1270 in simply 20 days?
20-year professional choices trader exposes his one-line chart strategy that reveals when to purchase and offer. Copy his trades, which have actually had balanced a 27% earnings every 20 days. Click on this link for gain access to
* Preserving their position, an expert from Chardan Capital continues to hold a Buy score for Praxis Accuracy Medication, targeting a cost of $330.
* Preserving their position, an expert from HC Wainwright & & Co. continues to hold a Buy score for Praxis Accuracy Medication, targeting a cost of $232.
* Constant in their assessment, an expert from Wedbush keeps a Underperform score on Praxis Accuracy Medication with a target cost of $77.
* Preserving their position, an expert from Guggenheim continues to hold a Buy score for Praxis Accuracy Medication, targeting a cost of $350.
* In a mindful relocation, an expert from Truist Securities reduced its score to Purchase, setting a cost target of $360.
Choices are a riskier property compared to simply trading the stock, however they have greater earnings capacity. Severe choices traders handle this threat by informing themselves daily, scaling in and out of trades, following more than one indication, and following the marketplaces carefully.
If you wish to remain upgraded on the most recent choices trades for Praxis Accuracy Medication, Benzinga Pro offers you real-time choices trades informs.